Cargando…

Enoxaparin versus dalteparin or tinzaparin in patients with cancer and venous thromboembolism: The RIETECAT study

BACKGROUND: Venous thromboembolism (VTE) is a frequent complication in patients with cancer and a leading cause of morbidity and death. OBJECTIVES: The objective of the RIETECAT study was to compare the long‐term effectiveness and safety of enoxaparin versus dalteparin or tinzaparin for the secondar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Trujillo‐Santos, Javier, Farge‐Bancel, Dominique, Pedrajas, José María, Gómez‐Cuervo, Covadonga, Ballaz, Aitor, Braester, Andrei, Mahé, Isabelle, Villalobos, Aurora, Porras, José Antonio, Monreal, Manuel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164243/ https://www.ncbi.nlm.nih.gov/pubmed/35664535 http://dx.doi.org/10.1002/rth2.12736

Ejemplares similares

Analysis of clinical factors affecting the rates of fatal pulmonary embolism and bleeding in cancer patients with venous thromboembolism
por: Trujillo-Santos, Javier, et al.
Publicado: (2017)

Different Types of Statins and All-Cause Mortality during Anticoagulation for Venous Thromboembolism: Validation Study from RIETE Registry
por: Siniscalchi, Carmine, et al.
Publicado: (2020)

Meta regression analysis to indirectly compare dalteparin to enoxaparin for the prevention of venous thromboembolic events following total hip replacement
por: Dranitsaris, George, et al.
Publicado: (2011)

Natural history of patients with venous thromboembolism and hereditary hemorrhagic telangiectasia. Findings from the RIETE registry
por: Riera-Mestre, Antoni, et al.
Publicado: (2019)

Management of venous thromboembolism in patients with cancer: role of dalteparin
por: Linkins, Lori-Ann
Publicado: (2008)

Long-Term Anticoagulant Therapy of Patients with Venous Thromboembolism. What Are the Practices?
por: Mahé, Isabelle, et al.
Publicado: (2015)

Population Pharmacokinetic Analysis of Dalteparin in Pediatric Patients With Venous Thromboembolism
por: Damle, Bharat, et al.
Publicado: (2020)

Tinzaparin Sodium Pharmacokinetics in Patients with Chronic Kidney Disease: Practical Implications
por: Helfer, Hélène, et al.
Publicado: (2019)

The Role of Tinzaparin in Oncology
por: Dimakakos, Evangelos P., et al.
Publicado: (2017)

Tinzaparin for Long-Term Treatment of Venous Thromboembolism in Patients With Cancer: A Systematic Review and Meta-Analysis
por: Martínez-Zapata, M. José, et al.
Publicado: (2017)

Comparison of rivaroxaban and dalteparin for the long-term treatment of venous thromboembolism in patients with gynecologic cancers
por: Lee, Jang Ho, et al.
Publicado: (2019)

Prophylaxis of cancer-associated venous thromboembolism with low-molecular-weight heparin-tinzaparin: Real world evidence
por: Christopoulou, Athina, et al.
Publicado: (2022)

Cancer Histology and Natural History of Patients with Lung Cancer and Venous Thromboembolism
por: Ruiz-Artacho, Pedro, et al.
Publicado: (2022)

Prevention of venous thromboembolism with enoxaparin in bariatirc surgery
por: Woo, Hee Doo, et al.
Publicado: (2013)

Efficacy and Safety of Apixaban versus Dalteparin as a Treatment for Cancer-Associated Venous Thromboembolism: A Systematic Review and Meta-Analysis
por: Arce-Huamani, Miguel A., et al.
Publicado: (2023)

Tinzaparin vs. Nadroparin Safety and Efficacy in Neurosurgery
por: Wilhelmy, Florian, et al.
Publicado: (2021)

Cost-effectiveness analysis and budget impact of rivaroxaban compared with dalteparin in patients with cancer at risk of recurrent venous thromboembolism
por: de Jong, Lisa A, et al.
Publicado: (2020)

Safety of Enoxaparin as Venous Thromboembolism Prophylaxis After Rhytidectomy
por: Lisiecki, Jeffrey L., et al.
Publicado: (2019)

Risk of recurrent thromboembolic events according to treatment duration in patients with superficial vein thrombosis treated with intermediate dose of tinzaparin
por: Karathanos, Christos, et al.
Publicado: (2022)

Does dalteparin PROTECT better than heparin?
por: Przybysz, Thomas, et al.
Publicado: (2011)

Competing Risk Analysis for Evaluation of Dalteparin Versus Unfractionated Heparin for Venous Thromboembolism in Medical-Surgical Critically Ill Patients
por: Li, Guowei, et al.
Publicado: (2015)

Retrospective Evaluation of Intravenous Enoxaparin Administration in Feline Arterial Thromboembolism
por: Mitropoulou, Athanasia, et al.
Publicado: (2022)

Optimal Dosing of Enoxaparin in Critically Ill Patients with Venous Thromboembolism
por: Abdulla, Aliya, et al.
Publicado: (2023)

Dalteparin-sodium: Chest wall haematoma: case report
Publicado: (2022)

Venous thromboembolism and bleeding in critically ill patients with severe renal insufficiency receiving dalteparin thromboprophylaxis: prevalence, incidence and risk factors
por: Cook, Deborah, et al.
Publicado: (2008)

Fatal Events in Cancer Patients Receiving Anticoagulant Therapy for Venous Thromboembolism
por: Farge, Dominique, et al.
Publicado: (2015)

CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients
por: Lee, Agnes YY, et al.
Publicado: (2013)

Heparin/tinzaparin-sodium: Lack of efficacy: 3 case reports
Publicado: (2020)

Tinzaparin-sodium: Bleeding and deep venous thrombosis: case report
Publicado: (2022)

Weight-adjusted dosing of tinzaparin for thromboprophylaxis in obese medical patients
por: Pfrepper, Christian, et al.
Publicado: (2023)

Enoxaparin Dosing for Venous Thromboembolism Prophylaxis in Low Body Weight Patients
por: Dybdahl, Daniel, et al.
Publicado: (2019)

Dalteparin versus vitamin K antagonists for the prevention of recurrent venous thromboembolism in patients with cancer and renal impairment: a Canadian pharmacoeconomic analysis
por: Dranitsaris, George, et al.
Publicado: (2017)

Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial
por: Becattini, Cecilia, et al.
Publicado: (2021)

Lipoprotein lipase responds similarly to tinzaparin as to conventional heparin during hemodialysis
por: Mahmood, Dana, et al.
Publicado: (2010)

Extended-Duration Treatment of Superficial Vein Thrombosis of the Lower Limbs with Tinzaparin
por: Nikolakopoulos, Konstantinos M., et al.
Publicado: (2018)

Tinzaparin Safety in Patients With Cancer and Renal Impairment: A Systematic Review
por: Vathiotis, I. A., et al.
Publicado: (2021)

Intensive-Dose Tinzaparin in Hospitalized COVID-19 Patients: The INTERACT Study
por: Akinosoglou, Karolina, et al.
Publicado: (2022)

Venous Thrombosis within 30 Days after Vaccination against SARS-CoV-2 in a Multinational Venous Thromboembolism Registry
por: Bikdeli, Behnood, et al.
Publicado: (2022)

Bilateral spontaneous, simultaneous lower extremity hematomas in a patient on dalteparin()
por: Daggett, J.R., et al.
Publicado: (2013)

Clinical outcomes during anticoagulant therapy in fragile patients with venous thromboembolism
por: Moustafa, Farès, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_88fjrk7md0tsfe1g1gjd6isohk